Medical Director, ADHD

Company Overview

Tris Pharma, Inc. () is a leading privately‑owned U.S. biopharmaceutical company focused on development and commercialization of innovative medicines in ADHD, spectrum disorders, anxiety, pain and addiction, addressing unmet patient needs. With over 150 U.S. and international patents, we market several branded ADHD products in the U.S. and license our products in the U.S. and international markets. Our robust pipeline spans neuroscience and other therapeutic categories, powered by our proprietary science and technology.

Our science and technology make us unique, but our team members set us apart; they are the engine fueling Tris’ passion and innovation. Our colleagues understand the criticality of operating a successful business and take pride in the company’s success. Equally important is how we interact on a daily basis. We believe in each other and in respectful, open, and honest communication to support individual and team success.

We have an immediate opening in our Medical Affairs department in Monmouth Junction, NJ for an experienced Medical Director, ADHD
. The Medical Director serves as a key leader within the medical affairs team, overseeing the medical and scientific strategy for the company’s ADHD pharmaceutical portfolio. The position acts as the medical and scientific authority in the ADHD therapeutic area and works cross‑functionally with Commercial, Regulatory, R&D, Market Access, and other internal departments.

The Medical Director plays a pivotal role in planning, execution, and oversight of Phase IV/IIS trials, medical communication, and stakeholder engagement specific to ADHD. The role also serves as a senior liaison with global healthcare providers, regulatory agencies, researchers, and key opinion leaders (KOLs) in ADHD, contributing to both the strategic direction and operational excellence of the organization.

• Provides strategic leadership for the company’s ADHD product portfolio, focusing on advancing medical affairs goals in attention‑deficit/hyperactivity disorder. Develops and implements comprehensive Medical Operating Plans (MOPs) in collaboration with cross‑functional stakeholders, including Brand/Product Directors and Global Medical Affairs teams, tailored to ADHD indications.
• Leads the medical oversight and execution of company‑sponsored clinical studies, including Phase IV/IIS studies in ADHD, ensuring alignment with scientific objectives and business priorities.
• Supervises and reviews external investigator‑initiated research proposals, scientific initiatives, and dissemination strategies to ensure alignment with company ADHD goals.
• Acts as ADHD scientific and therapeutic area expert, supporting internal functions including commercial brand teams, regulatory affairs, and R&D.
• Leads organization and execution of advisory boards, investigator meetings, medical strategy forums, and internal scientific discussions focused on ADHD. Builds and maintains high‑level relationships with global KOLs in ADHD, academic institutions, managed care organizations, advocacy groups, and government/regulatory bodies.
• Ensures compliance with Good Clinical Practice (GCP), PhRMA code, and applicable regulatory guidelines in all ADHD medical affairs activities. Supports publication strategy for ADHD data, including development of abstracts, posters, manuscripts, and congress presentations in collaboration with medical writing and communications teams.
• Monitors and assesses scientific and industry trends in ADHD to provide expert insights on competitive landscape and therapeutic advancements. Serves as a senior medical advisor and strategic partner across the organization on all ADHD‑related matters.

• MD, PhD, or Pharm
  
  D with a focus in Adult Psychiatry, Child/Adolescent Psychiatry, Neurology, or a closely related specialty with focus on ADHD and minimum 10 years experience in the pharmaceutical or biotechnology industry within medical affairs or clinical research in positions of increasing technical responsibility (minimum 3 years in ADHD).
• Proven ability to design and lead Phase IV trials and post‑marketing clinical programs in…